News Roundup / Brazilian Pharma April 2020
Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates. Proposal to allow breaking of patents due to Covid-19…
Address: Praça São Marcos, 624 05455-050 – São Paulo – SP,Brazil
Tel: 0800-772-4656
Web: http://www.ferring.com.br/
In 1950 in Malmö, Sweden, Dr. Frederik Paulsen founded Laboratoriet Nordiska hormone, which in 1954 changed its name to Ferring.
A world leader in peptide hormones, Ferring was a pioneer in developing and selling pharmaceutical products based on natural hormones, the pituitary-produced peptide. Dr. Paulsen was convinced that these new compounds could be used to supplement deficiencies and abnormalities, making an invaluable role in the treatment of various diseases.
Five decades later, Dr. Paulsen’s predictions have proven inaccurate. Today, the peptides are widely used in various treatments of Ferring.
Over the past years Ferring has expanded its activities beyond its European base and now have subsidiaries operating in over 40 countries, including Brazil, which is the company’s fastest-growing subsidiary. Its annual turnover is 700 million and has over 3,000 employees. Over the next three to five years, the group aims to triple sales in Brazil.
Propess, BioGaia, DDAVP, Choragon, Bravelle, FemLab, Menogon
Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates. Proposal to allow breaking of patents due to Covid-19…
Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases. This agreement establishes an exchange…
Three seasoned pharma executives with a wealth of experience working in Brazil offer their insights on leadership strategies for success in the massive, but complex, Brazilian pharma market. …
Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves…
When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature…
“Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing…
Maria del Pilar Muñoz, vice-president in charge of M&A and Sustainability at Eurofarma, one of the largest and most innovative pharmaceutical companies in Brazil with operations in 20 countries across…
Luciano Marques, president of Alcon Brazil, provides insights into recent investments and innovative initiatives aimed at strengthening Alcon’s relationships with its partners and customers in Brazil, and also documents the…
Armando Correa Lopes Jr, managing director of Siemens Healthineers Brazil, provides insights into the main trends and challenges at the core of Brazil’s healthcare discussion and documents the contribution of…
Tatiane Galindo, executive director of Ortosintese, Brazil’s and Latin America’s leading implant company, provides insights into Ortosintese’s historical commitment to the highest quality standards and her ambitions to further bolstering…
Fernando Itzaina, president and CEO of FQM Group, originally Farmoquímica, provides inspiring insights into the threefold development vision favored by this rapidly growing pharmaceutical company, his commitment to continue exploring…
Prof. Dr. Luiz Calistro Balestrassi, founder and president of NEUROTEC® – Biomedical Research & Development Company from Itajubá-MG, Brazil, and his daughter Esperança Balestrassi, Neurotec´s executive director, discuss the past,…
See our Cookie Privacy Policy Here